These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 8200213)

  • 1. Toxicology of depot medroxyprogesterone acetate.
    Jordan A
    Contraception; 1994 Mar; 49(3):189-201. PubMed ID: 8200213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depo Provera: still controversial.
    Wren LM
    Int Health News; 1988 Feb; 9(2):2-3, 8. PubMed ID: 12179873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Food and Drug Administration and medroxyprogesterone acetate. What are the issues?
    Rosenfield A; Maine D; Rochat R; Shelton J; Hatcher RA
    JAMA; 1983 Jun; 249(21):2922-8. PubMed ID: 6221125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug regulation in the United States and the United Kingdom: the Depo-Provera story.
    Richard BW; Lasagna L
    Ann Intern Med; 1987 Jun; 106(6):886-91. PubMed ID: 2953290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depot medroxyprogesterone acetate pioneers. A retrospective study at a North Carolina Health Department.
    Potter LS; Dalberth BT; Cañamar R; Betz M
    Contraception; 1997 Nov; 56(5):305-12. PubMed ID: 9437559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decline in bone mineral density with stress fractures in a woman on depot medroxyprogesterone acetate. A case report.
    Harkins GJ; Davis GD; Dettori J; Hibbert ML; Hoyt RA
    J Reprod Med; 1999 Mar; 44(3):309-12. PubMed ID: 10202754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of pretreatment counseling on discontinuation rates in Chinese women given depo-medroxyprogesterone acetate for contraception.
    Lei ZW; Wu SC; Garceau RJ; Jiang S; Yang QZ; Wang WL; Vander Meulen TC
    Contraception; 1996 Jun; 53(6):357-61. PubMed ID: 8773423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, single blind comparative trial of norethindrone enanthate and depo-medroxyprogesterone acetate in Bangladesh.
    Swenson I; Khan AR; Jahan FA
    Contraception; 1980 Mar; 21(3):207-15. PubMed ID: 6446442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depo-Provera: a critical analysis.
    Minkin S
    Women Health; 1980; 5(2):49-69. PubMed ID: 6451987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Contraception with injectable long-acting preparation depo-provera].
    Prilepskaia VN; Kondrikov NI; Tagieva TT
    Akush Ginekol (Mosk); 1995; (3):7-10. PubMed ID: 7653732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depo Provera. Position paper on clinical use, effectiveness and side effects.
    Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
    Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The contraceptive use of depot medroxyprogesterone acetate.
    Hickey M; Fraser I
    Clin Obstet Gynecol; 1995 Dec; 38(4):849-58. PubMed ID: 8616981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Depo-Provera.
    Sharts-Hopko NC
    MCN Am J Matern Child Nurs; 1993; 18(2):128. PubMed ID: 8492647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives.
    Mainwaring R; Hales HA; Stevenson K; Hatasaka HH; Poulson AM; Jones KP; Peterson CM
    Contraception; 1995 Mar; 51(3):149-53. PubMed ID: 7621683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Return of fertility after discontinuation of depot medroxyprogesterone acetate and intra-uterine devices in Northern Thailand.
    Pardthaisong T; Gray RH; McDaniel EB
    Lancet; 1980 Mar; 1(8167):509-12. PubMed ID: 6102234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Some effects of depo-medroxyprogesterone acetate (DMPA): observations in the nursing infant and in the long-term user.
    Dahlberg K
    Int J Gynaecol Obstet; 1982 Feb; 20(1):43-8. PubMed ID: 6126406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
    Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Depot medroxyprogesterone. Management of side-effects commonly associated with its contraceptive use.
    Archer B; Irwin D; Jensen K; Johnson ME; Rorie J
    J Nurse Midwifery; 1997; 42(2):104-11. PubMed ID: 9107118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Timing of onset of contraceptive effectiveness in Depo-Provera users. II. Effects on ovarian function.
    Petta CA; Faúndes A; Dunson TR; Ramos M; DeLucio M; Faúndes D; Bahamondes L
    Fertil Steril; 1998 Nov; 70(5):817-20. PubMed ID: 9806559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA board investigates Depo-Provera safety.
    Contracept Technol Update; 1983 Mar; 4(3):25-7. PubMed ID: 12266161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.